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Objectives Pharmacogenetic panel-based testing 
represents a new model for precision medicine. A 
sufficiently powered prospective study assessing the 
(cost-)effectiveness of a panel-based pharmacogenomics 
approach to guide pharmacotherapy is lacking. Therefore, 
the Ubiquitous Pharmacogenomics Consortium initiated the 
PREemptive Pharmacogenomic testing for prevention of 
Adverse drug Reactions (PREPARE) study. Here, we provide 
an overview of considerations made to mitigate multiple 
methodological challenges that emerged during the design.
Methods An evaluation of considerations made when 
designing the PREPARE study across six domains: 
study aims and design, primary endpoint definition and 
collection of adverse drug events, inclusion and exclusion 
criteria, target population, pharmacogenomics intervention 
strategy, and statistical analyses.
Results Challenges and respective solutions included: 
(1) defining and operationalizing a composite primary 
endpoint enabling measurement of the anticipated effect, by 
including only severe, causal, and drug genotype-associated 
adverse drug reactions; (2) avoiding overrepresentation of 
frequently prescribed drugs within the patient sample while 
maintaining external validity, by capping drugs of enrolment; 
(3) designing the pharmacogenomics intervention strategy 
to be applicable across ethnicities and healthcare settings; 
and (4) designing a statistical analysis plan to avoid dilution 
of effect by initially excluding patients without a gene–drug 
interaction in a gatekeeping analysis.
Conclusion Our design considerations will enable 
quantification of the collective clinical utility of a panel of 
pharmacogenomics-markers within one trial as a proof-of-
concept for pharmacogenomics-guided pharmacotherapy 
across multiple actionable gene–drug interactions. These 
considerations may prove useful to other investigators 
aiming to generate evidence for precision medicine. 
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Introduction
One of the first applications of genetics in precision med-
icine is pharmacogenomics informed pharmacotherapy. It 
promises to personalize medicine by using an individu-
al’s germline genetic makeup, to guide optimal drug and 
dose selection [1,2]. This removes the traditional ‘trial 
and error’ approach of drug prescribing, thereby prom-
ising safer, more (cost-)effective drug treatment [3,4]. 
Since 2005, the Dutch Pharmacogenetics Working Group 
(DPWG) has systematically reviewed 102 potential 
gene–drug interactions resulting in 56 guidelines provid-
ing therapeutic recommendations [5,6]. In parallel, the 
Clinical Pharmacogenetics Implementation Consortium 
has reviewed over 360 potential gene–drug interactions 
resulting in 60 recommendations [7]. A promising model 
for delivering pharmacogenomics-guided pharmaco-
therapy is through pharmacogenomics panel-based test-
ing. At least 95% of the population carries at least one 
genetic variant that would result in a pharmacother-
apy adjustment according to the available guidelines. 
Furthermore, patients may over their lifetime be started 
on multiple drugs for which pharmacogenomics may be 
relevant [8,9]. In a panel-based model, multiple vari-
ants that affect drug response are tested simultaneously 
and stored in the electronic medical record (EMR) for 
future use. When a relevant drug is prescribed, the corre-
sponding pharmacogenomics guideline can be deployed 
by the clinical decision support system (CDSS) at the 
point of care, thereby enabling healthcare professionals 
to use clinically actionable pharmacogenomics informa-
tion during drug prescribing [10]. However, despite the 
demonstrated clinical utility of pre-emptive pharmacog-
enomics-testing for several individual gene–drug interac-
tions, significant implementation barriers remain [11–13].
A prominent barrier preventing widespread adop-
tion of pharmacogenomics panel-based testing is the 
lack of evidence supporting this approach. Although a 
number of small, randomized and observational stud-
ies have indicated the potential benefits of pharma-
cogenomics panel-based testing [14–17], a sufficiently 
powered prospective study assessing the clinical and 
cost-effectiveness of pre-emptive pharmacogenom-
ics-testing is yet to be executed [18]. Therefore, the 
Ubiquitous Pharmacogenomics Consortium initi-
ated the PREemptive Pharmacogenomic testing for 
Preventing Adverse drug Reactions (PREPARE) study, 
(ClinicalTrials.gov: NCT03093818). The PREPARE 
study aims to quantify the collective clinical utility and 
cost-effectiveness of a panel of pharmacogenomics-mark-
ers to guide dose and drug selection in reducing the risk of 
clinically relevant adverse drug reactions (ADRs) [19,20], 
and thereby providing clinical outcome data which has 
been cited as a contributing factor preventing uptake of 
pharmacogenomics [21]. The PREPARE study is also an 
implementation study aiming to assess the process indi-
cators for implementation.
This paper outlines the multiple methodological and 
logistical challenges that were encountered while design-
ing and operationalizing the PREPARE study, and the 
solutions developed to overcome these challenges. 
Similar difficulties are likely to confront other investi-
gators aiming to generate evidence to show the utility 
of gene panel tests affecting multiple drugs in different 
therapeutic areas.
Methods
An evaluation of the challenges was undertaken across 
the following domains: study aims and design, primary 
endpoint definition and collection of adverse drug 
events, inclusion and exclusion criteria, target population, 
pharmacogenomics intervention strategy, and statistical 
analyses. The final design has previously been published 
elsewhere [19] (see Box 1 for a brief overview).
Results
The following sections discuss challenges and 
respective solutions considered by the Ubiquitous 
Pharmacogenomics Consortium when designing the 
PREPARE study. Figure 1 provides an overview of these 
challenges and the respective solutions.
Study aim and design
In the context of precision medicine, several fundamental 
options for generating evidence have been suggested such 
as observational research designed to identify modifiers 
of the effectiveness of interventions; subgroup analyses 
and interaction testing in standard randomized controlled 
trials (RCTs) of intervention effectiveness; or dedicated 
precision medicine RCTs that directly compare targeted 
vs. untargeted intervention approaches [22]. When gener-
ating evidence for pharmacogenomics effectiveness, we 
may envision an observational study wherein the availa-
ble guidelines are implemented prospectively and com-
pare a defined outcome with a historical control group, 
as recently performed for the dihydropyrimidine dehy-
drogenase gene (DPYD)–fluoropyrimidine interaction 
[23]. However, historical controls may likely only be fea-
sible for patient populations who are closely monitored, 
such as those on high-risk drugs like fluoropyrimidines. 
Additionally, it is not considered ethical to prospectively 
recruit a control group for gene–drug interactions where 
there is sufficient evidence for clinical implementation as 
for example abacavir hypersensitivity. On the other hand, 
many drugs included in the DPWG guidelines are low-
risk primary care drugs for which close monitoring is not 
routinely performed. Therefore, these studies are prone 
to certain forms of bias, such as information bias or selec-
tion bias.
An RCT can also, of course, be used to generate evi-
dence. Indeed, several RCTs have provided gold-stand-
ard evidence showing the clinical utility of individual 
gene–drug interactions to guide dosing [3,24–26] and 
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Box. 1
PREPARE study design in brief. PREPARE, PREemptive Pharmacogenomic testing for prevention of Adverse drug Reactions.
drug selection [27,28]. However, the DPWG has recom-
mendations for 51 gene–drug interactions, most of which 
have been developed in the absence of RCTs. Some 
argue that gold-standard RCT evidence is required for 
each gene–drug interaction before undertaking clinical 
implementation [18]. By contract, others have argued 
that a mandatory requirement for prospective evidence 
to support the clinical validity for pharmacogenomics is 
Copyright © 2020 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
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incongruous and excessive [29–32]. We support the latter 
view because generating gold-standard evidence for each 
of the 51 individual gene–drug interactions separately 
would require large amounts of funding which may be 
unrealistic. In addition, it may not be feasible to conduct 
RCTs for specific gene–drug interactions where the antic-
ipated efficacy is only observed after a long follow-up. For 
example, the improved efficacy of tamoxifen by guiding 
dose on CYP2D6 genotype may only be observed after 
an estimated 10-year follow-up [33]. It is important to 
note that nonpharmacogenomics interventions, such as 
dose adjustment of renally excreted drug in response to 
impaired kidney function, has been widely implemented 
in the absence of RCTs validating its effectiveness for 
each individual drug. Genetic exceptionalism has been 
held responsible for the double standard [34].
Regardless of the inconvenience, there is still a need for 
evidence showing patient benefit and cost-effectiveness 
to enable implementation of pharmacogenomics-guided 
drug dose and drug choice. Therefore, the Ubiquitous 
Pharmacogenomics Consortium decided on a novel way 
to evaluate the (cost-)effectiveness of pharmacogenom-
ics-guided pharmacotherapy. Instead of conducting 51 
separate RCTs (one for each DPWG guideline), the con-
sortium set out to quantify the collective clinical utility of 
a panel of pharmacogenomics-markers (50 variants in 13 
pharmacogenes) within one trial (the PREPARE study) 
for proof-of-concept across multiple potentially clinically 
relevant gene–drug interactions.
Primary endpoint definition
The final defined primary endpoint is described in Fig. 2. 
Since the DPWG guidelines encompass a broad range of 
gene–drug interactions, the resulting effects on patient 
outcomes are heterogeneous and therefore difficult to 
capture within one endpoint. Possible universal end-
points measuring these heterogeneous effects could have 
been quality of life (QoL) or overall survival (OS). On 
the other hand, anticipated asymptomatic effects are not 
Fig. 1
An overview of challenges encountered by the Ubiquitous Pharmacogenomics Consortium and respective solutions utilized.
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captured with QoL, and the follow-up time to capture 
effects on OS require long follow-up times. Therefore, 
we decided to define the primary endpoint as the pre-
vention of clinically relevant ADRs as 90% of the DPWG 
guidelines aim to decrease the risk of ADRs (Table 1). 
Clearly, gene–drug interactions that lead to improved 
efficacy, such as that associated with CYP2C19 polymor-
phism and omeprazole efficacy to increase Helicobacter 
pylori eradication, would not contribute to this defined 
endpoint. Therefore, these gene–drug interactions were 
excluded from the study.
Most of the DPWG guidelines recommend a dose 
decrease. Thus, theoretically the risk of ADRs will 
decrease in the intervention arm and as a result, one 
might be suspicious of unintended decreased efficacy 
because of this dose lowering. Therefore, more generally, 
one may argue that by using this endpoint we are una-
ble to conclude a reduction of ADRs in the absence of 
decreased efficacy unless the lack of efficacy is perceived 
as an ADR. In this context, an ideal control arm would 
be one where the doses of randomly selected controls, of 
which genotypes are unknown, are also decreased. This 
is; however, considered unethical. Nevertheless, since 
the DPWG dose adjustments are calculated based on 
pharmacokinetic studies, the anticipated drug exposure 
among those with variant genotypes treated with a guide-
line-recommended lowered dose, are expected to have 
similar drug exposures to those with wildtype genotypes 
treated with normal doses. This was confirmed in a phar-
macokinetic sub-study among patients carrying DPYD 
variants who were treated with a lower fluoropyrimidine 
dose [23]. Still, one could argue that decreased efficacy is 
a significant outcome that should be measured, to place 
the results into context. Potentially, this could be inferred 
from surrogate endpoints, such as drug discontinuation, 
within PREPARE.
Fig. 2
The composite primary outcome is the occurrence of causal (definite, probable or possible), clinically relevant (classified as CTCAE grades 2, 3, 
4, or 5), drug–genotype associated ADR, attributable to the index drug, within 12 weeks of index drug initiation. For oncology patients receiving 
fluorouracil, capecitabine, tegafur, or irinotecan, only hematological toxicities of CTCAE grades 4–5 and nonhematological toxicities of CTCAE 
grades 3–5 will be considered clinically relevant. CTCAE, Common Terminology Criteria for Adverse Events.
Copyright © 2020 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
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Simply defining a composite of ADR occurrence as an 
endpoint is insufficiently sensitive to measure the effect 
of pharmacogenomics-guided prescribing for two rea-
sons. First, since patients enrolled are often on multiple 
drugs, we need to distinguish between ADRs related and 
unrelated to the drug of enrollment. Secondly, measur-
ing only the ADR incidence, in the absence of severity, 
is less meaningful clinically. To improve sensitivity of the 
composite endpoint to these two factors, we incorporated 
both causality and severity assessments (Fig. 2). To mini-
mize measurement error, we selected systematic and val-
idated methodologies for assessments and decided upon 
thresholds for clinical relevance.
The composite endpoint includes also the third assess-
ment, further aiming to increase sensitivity to the 
endpoint to measure the intended effects of the phar-
macogenomics intervention. If we were to include all 
reported ADRs in the composite endpoint, it would dilute 
the effects of the pharmacogenomics intervention, as 
other ADRs, which may not be preventable by the inter-
vention, would be included. Therefore, to avoid dilution, 
the composite endpoint only includes drug-genotype 
associated ADRs where the increase in ADR incidence is 
known to be associated with a genotype, in keeping with 
the DPWG guidelines (Table 2). As an example, TMPT 
poor metabolizers or intermediate metabolizers who 
receive a lower dose of thiopurines have a 10-fold lower 
risk of severe leucopenia [26]. It is also plausible that 
there may be a reduction of other ADRs, which are not 
included in the DPWG guidelines because of lack of evi-
dence. In this situation, limiting the composite endpoint 
only to published drug–genotype associated ADRs may 
underestimate the effect of pharmacogenomics-guided 
prescribing. To avoid this, all ADRs experienced by par-
ticipants are being collected and assessed regarding their 
association with the predicted phenotype of the gene of 
interest thereby supporting the discovery of novel associ-
ations. This will be further reinforced by work aiming to 
undertake sequencing of pharmacogenes in patients with 
extreme phenotypes.
The time between drug initiation and the onset of ADRs 
was also considered when defining the time-window for 
the primary endpoint. A literature review showed that a 
12-week window would cover the majority of drug–gen-
otype associated ADRs. Additionally, when not dose-ti-
trated, all drugs included will have reached steady-state 
at 12 weeks, making it likely that most intrinsic ADRs 
would have occurred. Nevertheless, the selection of the 
time-window was complicated by the fact that we expect 
both on-target (type A) and off-target (or idiosyncratic) 
(type B) ADRs to be prevented by the pharmacogenom-
ics intervention. On-target ADRs are often related to the 
causal drug’s pharmacology and therefore the time-of-
onset is, in general, more predictable than idiosyncratic 
ADRs. As an example, on-target ADRs associated with 
amitriptyline such as anticholinergic effects and cardi-
otoxicity would be expected to be preventable within 
the time-frame of the primary end-point [35]. Off-target 
ADRs, which would potentially be preventable, include 
Table 1 An overview of actionable Dutch Pharmacogenetics 
Working Group guideline and their primary anticipated effects 
when used to guide dose and drug selection based on the sys-
tematic review of literature underlying the guidelines
Gene Drug




CYP2B6 Efavirenz X  
CYP2C19 Citalopram X  
Clomipramine X X
Clopidogrel  X
Escitalopram X  




Sertraline X  
Voriconazole X X
CYP2C9 Phenytoin X  
Warfarin X  
CYP2D6 Amitriptyline X X
Aripiprazole X  
Atomoxetine X X




Eliglustat X  
Flecainide X X
Haloperidol X X










CYP3A5 Tacrolimus  X
DPYD Fluorouracil/capecitabine X  
Tegafur X  
F5 Estrogen contraceptive agents X  
HLA-A Carbamazepineb X  
HLA-B Abacavira X  
Allopurinola X  
Carbamazepineb X  
Carbamazepineb X  
Phenytoin X  
Flucloxacillin X  
Lamotriginea X  
Oxcarbazepinea X  
NUDT15 Azathioprine/mercaptopurine X  
Tioguanine X  
SLCO1B1 Atorvastatin X  
Simvastatin X  
TPMT Azathioprine/mercaptopurine X  
Tioguanine X  
UGT1A1 Irinotecan X  
VKORC1 Acenocoumarol X  
Phenprocoumon X  
Warfarin X  
Clozapine and oxycodone were initially drugs of enrolment for the PREPARE 
study but updates in the Dutch Pharmacogenetics Working Group guidelines 
concluded that these were no longer related to actionable drug-gene interactions.
PREPARE, PREemptive Pharmacogenomic testing for prevention of Adverse 
drug Reactions.
aNot included as a drug of enrolment in PREPARE.
bHas been removed as a drug of enrolment during study.
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flucloxacillin-induced liver injury, which occurs after 
an average of 23.4 days [36]. By contrast, statin-induced 
myopathy can sometimes fall outside this time window. 
A large observational study showed more than half of 
statin-induced myopathy cases were reported in the first 
year of drug initiation; indicating at least half of cases 
were reported far outside a 12-week time-window [37]. 
Yet, with an increasing time-window, the overall causal-
ity to the index drug decreases [38]. Therefore, settling 
a 12-week time-window is pragmatic and optimizes 
balance between the ability to determine causality and 
coverage of most of the ADRs expected to be prevented. 
Clearly, we will miss some ADRs outside this time-win-
dow, and possibly under-estimate the effect, and this 
should be borne in mind when placing the results of the 
PREPARE study into context.
Primary endpoint collection
The operationalization of data collection to support the 
severity and causality assessments required additional 
consideration because of to the broad range of anticipated 
ADRs. This was in context of the fact that extracting 
ADR data retrospectively from EMRs can be difficult. 
Prospective collection of data in PREPARE after assess-
ment of the patient was therefore felt to be the most accu-
rate method. To capture as much information as possible on 
the occurrence of ADRs, we use three sources and concur-
rently collect information to support severity and causality 
assessments. Information is obtained from patients during 
scheduled follow-up (both online surveys and interviews), 
clinician reports, and extraction from the EMR. Patient 
interviews consist of open-ended questions, designed to 
uncover any ADRs, which the patients may have endured. 
On the other hand, a limitation of this methodology is the 
inability to uncover ADRs which are asymptomatic, such 
as citalopram-induced corrected QT-interval (QTc) pro-
longation, as ECGs are not routinely performed, poten-
tially underestimating the occurrence of ADRs. However, 
once the ADR manifests symptomatically, such as Torsade 
de Pointes, it will contribute to the endpoint.
To ensure systematic assessment of the defined compos-
ite endpoint, we utilized standardized methods for assess-
ment of severity and causality; the Common Terminology 
Criteria for Adverse Events (CTCAE) and Liverpool 
Causality Assessment Tool (LCAT), respectively.
In order to undertake severity assessment, using 
CTCAE, we require different types of data depending 
on the ADR reported. For example, to assess severity of 
a drug-induced dry mouth, we require data on the inter-
vention required (grade 1: symptomatic without dietary 
alteration; grade 2: oral intake alterations; grade 3: tube 
feeding), whereas when assessing the severity of neu-
tropenia, we require data on neutrophil counts (grade 3: 
ANC<1000/mm3; grade 4: life-threatening consequences; 
grade 5: death). This content is collected both directly 
from patients during follow-up (e.g. How much did the 
side effect interfere with your usual daily activities? Did 
it limit your self-care activities?) and from the EMR. To 
minimize the impact of recall bias, patients are contacted 
at t = 4 and t = 12 weeks after index drug initiation. We 
note that a previous study indicated that a recall period 
of 1 week corresponded best to daily reporting, but it con-
cluded that a 4-week recall was also acceptable [39] in 
order to reduce the burden of patient follow-up on each 
individual site (staff and patients). The initial t = 4-week 
follow-up is within the acceptable range, and we expect 
most ADRs to be reported within this time.
Causality assessment was formalized with the LCAT, 
which requires information on the start- and end-date of 
both the index drug and the ADR, the severity of the 
ADR and the outcome of the re-challenge, when applica-
ble. As with the severity assessment, data to support the 
causality assessment is collected from direct question-
ing of patients after the report the adverse event during 
scheduled follow-up (e.g. Did you lower the dose or tem-
porarily stop taking the index drug after having the side 
effect? Did this reduce the side effect?).
In contrast to severity and causality assessment, there 
is no standardized method available for assessment of 
drug-genotype association. Therefore, to ensure unbi-
ased assessment, an algorithm will be used to perform 
the analysis at study completion, to ensure consistent 
pharmacogenomics literature across assessments. This 
algorithm is being created by an expert panel, blinded 
to patient allocation. It is based on ADRs associated with 
certain genotypes in the literature underlying the DPWG 
(Table 1) and the ADRs reported in a drug’s Summary of 
Product Characteristics.
Study design and blinding
To account for center-heterogeneity and time-depend-
ent differences, PREPARE is a cluster-randomized cross-
over trial comparing pharmacogenomics-guided strategy 
with standard care using a single cross-over moment. 
Clusters are formed by the countries participating in 
the study. The choice of a single cross-over time-point, 
instead of many, is dictated by the substantial logistic 
effort to switch between strategies. Without randomi-
zation, all countries could have started with standard of 
care followed by pharmacogenomics-guided prescribing 
synchronously. This could potentially introduce time-de-
pendent differences, for example, healthcare professional 
(HCP) awareness and knowledge of pharmacogenomics 
may increase over time. Risk of protocol violation of the 
crossover approach results from centers randomized to 
begin with the pharmacogenomics-strategy, being una-
ble to switch back to standard of care, resulting in an 
absence of a site-specific control arm. In our project, 
this has not occurred. A statistically more powerful alter-
native, for cluster randomization, would be individual 
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randomization at the patient level. This would likely be 
logistically challenging and error-prone for the participat-
ing clinicians, who would need to follow different strate-
gies for different patients simultaneously and the design 
was therefore excluded in the design phase of this study.
Certainly, blinding both patients and clinicians from the 
pharmacogenomics-test results would optimize scien-
tific rigor and prevent potential information bias [40]. 
Nevertheless, this was not deemed feasible and therefore 
an open-label approach was chosen. This may potentially 
affect results as pharmacogenomics-testing could pro-
vide false reassurance to wild-type patients enrolled in 
the intervention arm that a given drug will be effective 
and cause minimal side effects; and conversely, may also 
motivate patients with variant genotypes to report side 
effects. By contrast, patients enrolled in the intervention 
arm may also be susceptible to the nocebo effect [41]. 
This may be the case when patients are told they have 
an actionable gene-drug interaction, requiring immediate 
pharmacotherapy adjustment, although they have already 
been using an untailored regimen for a number of days. 
In this case, the patient may be more prone to perceiving 
ADRs, which otherwise may not have been perceived. 
This notion is supported by a recent study that showed 
that learning one’s genetic risk may evoke physiological 
changes consistent with the expected risk profile [42]. 
This underlines the importance of both the clinician’s 
role in communicating the pharmacogenomics results 
and their effects on the drug regimen and the ability of 
patients to understand the probabilistic nature of the test 
result. Despite these issues, an advantage of performing 
an open-label study is that it closely mimics real-world 
application of pharmacogenomics, where both patients 
and clinicians are aware of the pharmacogenomics result. 
It is also an opportunity to study the interactions between 
patients and clinicians when implementing pharmacog-
enomics. Finally, in an effort to minimize differences in 
participant experience between intervention and control 
arms, we are providing control patients with a mock safe-
ty-code card, given that intervention patients also receive 
their pharmacogenomics recommendations on a safe-
ty-code card.
Inclusion and exclusion criteria
Some drugs are more frequently prescribed than oth-
ers in routine care. To avoid overrepresentation of those 
drugs, which are frequently prescribed within the patient 
sample, a number of potential solutions were considered. 
First, imposing a cap to limit the maximum portion (10%) 
of patients enrolled in a particular drug. This option is fea-
sible and would have a positive effect on clinical relevance 
since it would provide the opportunity for a minimum 
of 10 eligible drugs to be enrolled in the study. Second, 
reflecting the enrolment of drugs in the study to prescrip-
tion frequencies in the European population. This option 
would be feasible, but drugs, which are uncommonly 
prescribed, will not be equally represented as commonly 
Table 2 An overview of actionable Dutch Pharmacogenetics Working Group guideline and their primary anticipated effect based on the 
literature underlying the Dutch Pharmacogenetics Working Group guidelines
DPWG Clinical  
relevance score CTCAE score Adverse drug event
AA#:  Positive clinical effect.
AA: No kinetic effect: No change or nonsignificant change of kinetic parameters. No clinical effect: no change or 
nonsignificant change of clinical parameters.
A: Kinetic effect: 0 Significant change of kinetic parameters. Clinically insignificant effect: increase in QTc interval not 
higher than 470 ms for women or 450 ms for men or an absolute increase in QTc time of no more 
than 60 ms; increase INR to 4.5; expected asymptomatic bradycardia.
B: Clinical effect, short-
term discomfort (<48 
h) without residual 
symptoms:
1: Mild; asymptomatic or mild 
symptoms; clinical or diagnostic 
observations only; intervention not 
indicated.
Reduced decrease in resting heart rate; decrease in exercise tachycardia; short-term symptomatic 
bradycardia; insufficient pain relief with oxycodone; side effects due to increased bioavailability of 
atomoxetine (decreased appetite, insomnia, sleep problems, depressed mood, early awakening); 
neutropenia> 1.5 × 109/L; leukopenia> 3.0 × 109/L; thrombocytopenia> 75 × 109/L; moderate 
diarrhea without affecting daily activities; reduced rise in glucose levels in glucose tolerance test; 
muscle complaints with creatine kinase <3 times the upper limit of normal.
C: Clinical effect, 
long-term discomfort 
(48–168 h) without 
residual symptoms:
2: Moderate; minimal, local or 
Noninvasive intervention indicated; 
limiting age-appropriate instrumen-
tal ADL.
Failure therapy for a nonserious condition: tricyclic antidepressants, atypical antipsychotics; 
extrapyramidal side effects, parkinsonism (shaky/shaky); side effects due to increased plasma 
concentration of tricyclic antidepressants, metoprolol, propafenone (central side effects such as 
dizziness); long-term symptomatic bradycardia; increase INR to 4.5–6.0; neutropenia 1.0–
1.5 × 109/L; leukopenia 2.0-3.0 × 109/L; thrombocytopenia 50–75 × 109/L; muscle complaints with 
creatine kinase 3–10 times the upper limit of normal.
D: Clinical effect, 
long-term discomfort 
(>168 h) or residual 
symptoms or disability:
3: Severe or medically significant but 
not immediately life- threatening; 
hospitalization or prolongation of 
hospitalization indicated; disabling; 
limiting self-care ADL
Failure of prophylaxis in atrial fibrillation; venous thromboembolism; reduction of inhibition of platelet 
aggregation by clopidogrel; side effects due to increased plasma concentration of phenytoin; 
increase INR > 6.0; neutropenia 0.5–1.0 × 109/L; leukopenia 1.0–2.0 × 109/L; thrombocytopenia  
25–50 × 109/L; severe diarrhea; myopathy (muscle complaints with creatine kinase  ≥10 times the 
upper limit of normal); hospitalization due to bradycardia.
E: Failure of (in the short- 
or long-term) life-saving 
therapy:
4: Life-threatening consequences; 
urgent intervention indicated
Prevention of breast cancer recurrence; arrhythmias; expected bone marrow depression; neutropenia 
<0.5 × 109/L; leukopenia <1.0 × 109/L; thrombocytopenia <25 × 109/L; life-threatening effects of 
diarrhea; life-threatening side effects (such as SJS, TEN or DRESS); rhabdomyolysis.
F: Death: 5: Death related to adverse event Arrhythmias; unexpected bone marrow depression
ADL, activities of daily living; CTCAE, Common Terminology Criteria for Adverse Events; DPWG, Dutch Pharmacogenetics Working Group; DRESS, drug rash with 
eosinophilia and systemic symptoms; SJS, Stevens-Johnson Syndrome; TEN, toxic epidermal necrolysis, QTc, corrected QT-interval.
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prescribed drugs thereby decreasing the generalizability 
of the results. Third, to only select gene–drug interac-
tions that we anticipate having the greatest effect size 
and to maximize the proportion of patients enrolled on 
the corresponding drug. Selecting this option; however, 
would synthetically increase the effect size of the inter-
vention, thereby leading to a biased outcome with low 
generalizability. After consideration, the first option was 
chosen and implemented since it was most feasible and 
is likely to have a positive effect on the generalizability 
of results across all 41-index drugs (Fig. 3). In order to 
avoid ethical problems and maintain equipoise, countries 
already implementing specific gene–drug interactions as 
part of routine care are exempt from enrolling patients on 
the corresponding drugs. For example, pre-emptive rou-
tine DPYD testing is standard of care in the Netherlands 
and therefore patients initiating fluoropyrimidines are 
not being recruited in the Netherlands, but are being 
recruited in other countries where DPYD testing is not 
standard of care.
Target setting and population
Whether pharmacogenomics-guided pharmacotherapy is 
effective in reducing ADRs is partially dependent on the 
health-care system in which it is applied, as the following 
vary across healthcare systems beliefs and knowledge 
about pharmacogenomics amongst HCPs [43], adherence 
to pharmacogenomics guidelines, patient baseline health, 
cultural aspects, the usability of the CDSS, and the infra-
structure of the healthcare systems in which it is imple-
mented. This underlines the importance of performing 
this experiment in a number of healthcare settings, 
where these variables may vary, to maximize external 
validity. Each of the seven countries has its own health-
care system ranging from highly automated electronic 
CDSS (such as in The Netherlands) to paper-based sys-
tems (such as in Slovenia and Greece). The considera-
tions made in developing local solutions for CDSS have 
been published previously [44]. An added advantage 
is the ability to assess implementation process metrics 
across diverse healthcare systems, which may be help-
ful for future implementation efforts outside the scope 
of this trial. However, current sites are considered early 
adopters of pharmacogenomics, potentially limiting the 
external validity.
Whether pharmacogenomics-guided pharmacotherapy is 
effective in reducing ADRs is also dependent on the inter-
section of variants included in the panel and the ethnicity 
of the target population. Allele frequencies in pharmaco-
genes vary significantly between different ethnic groups 
Fig. 3
Index drugs are capped at 10% of the total sample, 5% for each arm. This 5% is in turn equally divided over two groups of sites (2.5% in each), 
equally providing all sites with the opportunity to enroll patients on certain index drugs; the first group being those starting with the intervention 
arm and the second group being those staring with the control arm. Index drug enrollment is monitored centrally in real-time to ensure cessation of 
enrolment of index drugs once their cap is reached.
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[45]. As a result, the incidence of patients carrying an action-
able gene-drug interaction may also vary. Additionally, cer-
tain gene-drug interactions may only be relevant in some 
ethnic groups [46]. In an effort to optimize the applica-
bility of the PREPARE results, the variants selected for 
ubiquitous pharmacogenomics panel should have at least 
an overall minor allele frequency (MAF) ≥1%, or the MAF 
in selected populations must be (European/Asian/African) 
≥1%. The considerations made in developing the ubiqui-
tous pharmacogenomics panel (pharmacogenomics pass-
port) have been published previously [47]. Tagging single 
neucleotide polymorphisms (SNPs) were included in the 
initial panel selection to assess HLA-B*15:02 and HLA-
A*31:01 status. However, the tagging SNPs only appeared 
suitable in subjects of Asian origin and not in a cohort of 
subjects of predominantly Caucasian origin. As a result, 
these tagging SNPs were removed from the panel and car-
bamazepine was removed as a drug of enrolment.
Pharmacogenomics intervention strategy
As literature underlying pharmacogenomics accumulates 
over time, the DPWG guidelines are regularly updated. In 
the PREPARE study, these updates are also implemented 
regularly, as we felt it unethical not to treat patients with 
the most up-to-date knowledge. However, one may 
argue that this imposes limitations on the scientific rigor 
of determining the effect of the intervention since it is 
not constant over time. However, it is inevitable that the 
guidelines will be updated regularly even after comple-
tion of the PREPARE study. Therefore, updating the 
guidelines within the study reflects the real-world aspects 
of the intervention more accurately than using out-of-
date guidelines for the sake of scientific rigor. Examples 
of this during the study are the removals of oxycodone 
and clozapine as drugs of enrolment. At study initiation, 
the CYP2D6–oxycodone and CYP1A2–clozapine interac-
tions were classified as actionable interactions requiring 
pharmacotherapy adjustment for at least one phenotype 
category. However, after preplanned updates of these 
guidelines by the DPWG, both were no longer considered 
actionable. Therefore, these drugs cannot result in a phar-
macotherapeutic recommendation and were removed as 
drugs of enrolment. Additionally, CYP1A2 was removed 
from the panel since there remained no actionable drug-
gene interactions related to this gene. In addition to 
updates of DPWG guidelines, new guideline for novel 
gene–drug interactions are also developed. For example, 
for CYP2D6–brexpiprazole, HLA-B–allopurinol, HLA-
B–lamotrigine, and HLA-B–oxcarbazepine. However, 
to avoid unequal number of patients on these drugs in 
study and control arms, these drugs were not added to the 
list of drugs of enrolment throughout the study. Indeed, 
removal of oxycodone and clozapine also resulted in an 
unequal number of patients on these drugs in study and 
control arms. However, the resulting nonactionability of 
the DPWG updates could not have been foreseen and 
therefore is substantiated.
The timing and methodology of delivering the relevant 
actionable DPWG guideline to treating clinicians may also 
have an effect on outcomes. To quantify the effectiveness of 
pharmacogenomics to prevent ADRs, one would prefer to 
initiate the ‘correct’ drug and dose, tailored to the patient’s 
pharmacogenomics profile. However, this would require 
patients to delay the initiation of their pharmacotherapy 
while awaiting the turn-around of their pharmacogenomics 
test result. We felt this would be unethical, especially for 
analgesic therapies. For this reason, we have imposed a max-
imum 7-day turn-around time in which the gene important 
to the drug of enrollment and the corresponding DPWG 
guideline should be reported to the treating physician. 
However, a limitation of this delay is the potential under-
estimation of the true effect of pharmacogenomics-guided 
pharmacotherapy, since patients start the index drug on an 
unoptimized dose or drug to bridge the turn-around time 
and the risk of ADRs may increase with an increasing num-
ber of days using the un-optimized dose. It will be possible 
to adjust for this in a per-protocol analysis.
Statistical analysis
The added value of testing a panel of pharmacogenomics 
markers as opposed to multiple single genes is the abil-
ity to reuse the pharmacogenomics-panel results in the 
future without the logistical hassle of turn-around time. 
However, this added value is not captured by the primary 
statistical analysis since it is limited to ADRs attributed 
to the index drug and excludes ADRs attributed to sub-
sequent drugs. Our reasoning for this is to avoid selection 
bias since patients initiating subsequent drugs use more 
concomitant drugs and are therefore at higher risk of 
experiencing more ADRs. Nevertheless, there is a need 
to quantify the effectiveness of ADR prevention through 
pre-emptive panel testing. Since PREPARE enables data 
collection not only for the index drug but also for (multi-
ple) subsequent drugs, we are able to address this need 
by re-running the primary analysis using ADRs attrib-
uted to subsequent drugs in a secondary analysis.
Gatekeeping analysis
Traditional RCTs use strict eligibility criteria to select 
only patients in whom a benefit is most likely to be 
observed from the assessed intervention. However, with 
pharmacogenomics testing, we are unable to perform 
such a selection because the genotype is not known prior 
to recruitment. Only those patients with an actionable 
gene–drug interaction for the index drug may benefit 
from the pharmacogenomics intervention for the drug 
of enrolment. Therefore, comparison of the entire study 
arm to the entire control arm would underestimate the 
effectiveness for the subgroup of patients who may bene-
fit from the intervention. For example, a study by Coenen 
et al. [26] found screening for variants in TPMT did not 
reduce the overall proportions of patients with hema-
tologic ADRs during thiopurine treatment. However, 
within the subgroup carrying an actionable gene-drug 
Copyright © 2020 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
Considerations made designing the PREPARE study van der Wouden et al. 141
interaction, there was a 10-fold reduction in hematologic 
ADRs. To minimize the risk of an unjust nonsignifi-
cant outcome when comparing arms, we decided upon 
a gatekeeping analysis (Fig.  4), where the first analysis 
quantifies the effect among those who have an actiona-
ble gene-drug interaction. However, when applied in a 
clinical setting, an entire population will need to be gen-
otyped to be able to identify those who carry a variant 
genotype relevant for the drug to be used in the patient. 
This is addressed in the second analysis, where the effect 
of pharmacogenomics-guided pharmacotherapy among 
the entire screened population will be quantified.
Statistical model and estimand
To account for the clustered nature of the data, the anal-
ysis will be stratified by country, correcting for study 
center and other relevant covariates on the patient level. 
Analyses will be pooled using a meta-analysis. The 
composite endpoint is binary representing – in general 
– ADE severity 0/1 in one group and ADE severities 
2/3/4/5 in the other. We use logistic regression to assess 
the influence of the pharmacogenomics-intervention on 
the probability of transitions between these two groups. 
Transitions within the groups, for example between 
grades 3 and 4, are not considered by this analysis as not 
aligning with the implementation goal. The estimand 
of the primary analysis is, therefore, the odds ratio for 
transitioning between these two groups based on the 
intervention.
An ordered logistic regression (ordinal regression) is more 
powerful when the goal is to detect the influence of the 
intervention on lowering severity in general by choos-
ing as an outcome the ordinal ADEs (not grouping ADE 
grade). As such an approach can give additional insight 
into mechanisms underlying the effect of pharmacog-
enomics-intervention, ordinal regression will be per-
formed as a secondary analysis.
Fig. 4
Primary statistical analysis: a two-step gatekeeping analysis. First, a logistic regression analysis will be performed among patients who had an 
actionable drug-genotype combination. This analysis is first performed per country, and the log-odds are pooled in a forest plot. Only if this is sta-
tistically significant a second analysis will be performed: a logistic regression analysis among all patients included in the study. Again, this is first 
performed per country, and log-odds are pooled in a forest-plot.
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Extreme phenotypes
In addition to the aim of quantifying the clinical util-
ity of a pharmacogenomics-panel, the PREPARE study 
also aims to expand our understanding of genetic varia-
tion on drug response. The PREPARE study is a unique 
opportunity to identify and further investigate patients 
who express unexpected drug responses, known as 
extreme phenotypes. Three criteria for defining extreme 
phenotypes were devised to identify patients within 
PREPARE: (1) the physician considers the ADR impor-
tant, (2) ADR is of severity grade 3 or above, or in the 
case of hematological toxicity grade 4 or above, and (3) 
patient experienced (re)hospitalization as a result of 
the ADR. A major problem as a result of these criteria 
is that they are applied differently across study centers. 
In some cases, it is difficult to stratify a true ADR from 
disease-induced adverse events. To overcome this issue, 
interesting cases are identified from the existing list of 
extreme phenotypes. These are further analyzed for pos-
sible novel genetic variants or combination of variants by 
an initial genome-wide association study encompassing 
all relevant pharmacogenes and followed in special cases 
by whole genome sequencing. Based on the multitude of 
rare genetic variants uniquely present in specific individ-
uals, we believe this is an important step toward higher 
future predictability of genetically related ADRs.
Discussion
Future perspective of pharmacogenomics testing to 
optimize pharmacotherapy
The potential effectiveness of pharmacogenomics test-
ing to reduce on-target ADRs is determined by a number 
of factors including the ability of the tested variants to 
accurately predict the patient’s phenotype, the extent to 
which genetic variation affects target protein functional-
ity, the extent to which the target protein determines drug 
exposure and finally, the causal relationship between the 
drug of exposure and ADR risk. In the future, we expect 
a shift in the field regarding the first two determinants; 
phenotype prediction will become more accurate due to 
accumulating knowledge of the effects of individual var-
iants on enzyme and transporter functionality. Currently, 
phenotypes are predicted using a categorical approach. 
However, enzyme activity is usually normally distributed 
within a population and therefore is better described by a 
continuous phenotype scale. We envision a future where 
phenotypes can be predicted more precisely by using 
all of an individual’s genetic variation (common and rare 
variants), as opposed to limiting the assessment to only 
those variants included in a tested panel. Although we 
expect the variants in the ubiquitous pharmacogenomics 
panel to correctly predict most phenotypes, it may not be 
able to do so correctly for all patients, since rare, untested 
variants may also affect phenotype. As our understand-
ing of the effects of individual variants to inform phe-
notype prediction improves, we imagine that phenotype 
prediction will ultimately become substrate-specific as 
opposed to simply gene-specific. Thus, as our knowledge 
improves and increases resolution, we expect further 
improvements in the effectiveness of pharmacogenom-
ics testing to reduce ADRs. Looking even further for-
ward into the future pharmacogenomics profiles may be 
combined with other -omic profiles including the epig-
enome [48], microbiome [49], and metabolome [50], to 
further inform truly personalized, as opposed to stratified, 
prescribing.
Generating evidence for other precision medicine 
approaches
In this article, we have provided an overview of the 
challenges and respective solutions while designing the 
PREPARE study. We expect similar challenges to con-
front fellow investigators aiming to generate evidence 
for precision medicine approaches other than pharma-
cogenomics. Conventionally, evidence supporting novel 
interventions is generated by prospective trials. However, 
in an era where digitalization is driving data accumula-
tion and a concomitant increase in stratification of patient 
groups, we are moving towards utilization of real-world 
data to support precision medicine. Several authors have 
pointed out that precision medicine, and genomic med-
icine, in particular, would benefit from a convergence of 
implementation science and a learning health system 
approach to measure outcomes and generate evidence 
simultaneously [51,52]. However, this requires stand-
ardization of outcomes in EMRs to enable aggregation 
of phenotype data across large populations for both dis-
covery and outcomes assessment as part of implementa-
tion [21,53]. Many nationwide, large-scale initiatives are 
generating prospective longitudinal evidence supporting 
precision medicine approaches [54–57].
Generating evidence for pharmacogenomics: the 
PREemptive Pharmacogenomic testing for prevention 
of Adverse drug Reactions study
In conclusion, we have undertaken detailed consider-
ations to enable quantification of the collective clinical 
utility of a panel of pharmacogenomics-markers within 
one trial as a proof-of-concept for pharmacogenom-
ics-guided pharmacotherapy across multiple actionable 
gene–drug interactions. Although PREPARE will enable 
quantification of the clinical utility of a pharmacogenom-
ics panel, it may also potentially underestimate the effects 
due to delayed initiation of a pharmacogenomics-guided 
dose or drug choice because of our turn-around-time 
(<7 days), and thereby limit the primary endpoint which 
is the reduction of ADRs caused by the initiated drug. 
Further research is therefore needed to quantify the 
effectiveness of panel-based pharmacogenomics-guided 
pharmacotherapy in patients encountering multiple 
gene–drug interactions over a longer time-horizon. This 
can be achieved within a clinical trial, or a more practical 
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approach may be to use real-world data to estimate long-
term (cost-)effectiveness. PREPARE provides the frame-
work not only for future efforts in this area but also in 
providing the evidence base for ubiquitous adoption of 
pharmacogenomics-guided pharmacotherapy [58].
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